Anthony Gringeri

Institution Name: 
ImmunoCellular Therapeutics
Total Awards: 
1
Award Value: 
$5,391,016
  • Share
  • Print
  • PDF version

Awards as PI

Program Type Institution Grant Title Award Value
Clinical Trial Stage Projects ImmunoCellular Therapeutics A Phase III randomized double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy $5,391,016
Total:
$5,391,016.00